Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
NCT ID: NCT01203358
Last Updated: 2019-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
617 participants
INTERVENTIONAL
1991-01-31
1992-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aerosolized Surfactant in Neonatal RDS
NCT02294630
The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS
NCT03808402
Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial
NCT00000570
Efficacy of Surfactant and Perinatal Risk Factors in NRDS With Different Gestational Ages
NCT03385863
Optimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome
NCT04984057
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Surfactant 1
Exosurf Neonatal (Burroughs Wellcome Co.)
Exosurf
Infants received up to four intratracheal doses of the surfactant.
Surfactant 2
Survanta (Ross Laboratories)
Survanta
Infants received up to four intratracheal doses of the surfactant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exosurf
Infants received up to four intratracheal doses of the surfactant.
Survanta
Infants received up to four intratracheal doses of the surfactant.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NICHD Neonatal Research Network
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Vermont
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey D. Horbar, MD
Role: STUDY_DIRECTOR
University of Vermont
Elizabeth C. Wright, PhD
Role: PRINCIPAL_INVESTIGATOR
George Washington University
Avroy A. Fanaroff, MD
Role: PRINCIPAL_INVESTIGATOR
Case Western Reserve University
Sheldon B. Korones, MD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee
Seetha Shankaran, MD
Role: PRINCIPAL_INVESTIGATOR
Wayne State University
Charles R. Bauer, MD
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Jon E. Tyson, MD MPH
Role: PRINCIPAL_INVESTIGATOR
University of Texas
James A. Lemons, MD
Role: PRINCIPAL_INVESTIGATOR
Indiana University
Edward F. Donovan, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital Medical Center, Cincinnati
Barbara J. Stoll, MD
Role: PRINCIPAL_INVESTIGATOR
Emory University
David K. Stevenson, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
LuAnn Papile, MD
Role: PRINCIPAL_INVESTIGATOR
University of New Mexico
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Palo Alto, California, United States
Yale University
New Haven, Connecticut, United States
George Washington University
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
Indiana University
Indianapolis, Indiana, United States
Wayne State University
Detroit, Michigan, United States
University of New Mexico
Albuquerque, New Mexico, United States
Cincinnati Children's Medical Center
Cincinnati, Ohio, United States
Case Western Reserve University, Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States
University of Tennessee
Memphis, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
University of Vermont
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB, Shankaran S, Oh W, Fletcher BD, Bauer CR, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1993 Nov;123(5):757-66. doi: 10.1016/s0022-3476(05)80856-x.
Related Links
Access external resources that provide additional context or updates about the study.
NICHD Neonatal Research Network
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NICHD-NRN-0003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.